Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib

Summary

The purposes of this study are to determine: The pharmacokinetics (the amount of study drug in your blood and how long it takes the body to get rid of it) of the study drug and its metabolites (substances produced as the body breaks down the study drug) in participants with moderate or severe liver function impairment compared to participants with normal liver function (also known as a healthy volunteer). Pharmacokinetics (or PK) is the study of how your body absorbs, breaks down, and removes a study drug.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Healthy
• Hepatic Impairment

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1

Ages

18 to 80 years

Sex

All

Healthy volunteers

Accepted

Sponsor

SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

Last updated on ClinicalTrials.gov

October 14, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites